At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 131 enrolled
Drug / intervention
Prepandrix™ +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Immunogenicity and Safety of GlaxoSmithKline Biologicals' (Pre-) Pandemic Influenza Vaccine Prepandrix™ in Korean Subjects Aged 18 to 60 Years Old
In Brief
A Phase 4 clinical trial evaluating Prepandrix™ and Fluarix™ for Influenza. Completed, enrolled 131 participants across 4 sites.
Detailed Summary
This study will evaluate the immunogenicity and the safety of PrepandrixTM in Korean subjects. A second group of subjects will receive FluarixTM vaccine as control.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
CountriesSouth Korea
Collaborators--
Timeline
Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedNov 2012
Enrollment StartDec 2012
Primary CompletionDec 2013
TodayJul 2026
First PostedNov 21, 2012
Enrollment StartDec 5, 2012
Primary CompletionDec 17, 2013
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 13.6 years ago
Interventions
Prepandrix™biological
2 doses administered intramuscularly in the deltoid region of arm (non-dominant arm at Day 0 and dominant arm at Day 21).
Fluarix™biological
1 dose administered intramuscularly in the deltoid region of non-dominant arm.